Eric Jonasch, MD, on Von-Hippel Lindau Disease: Pazopanib Trial

2017 ASCO Annual Meeting
Tweet this page

Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the largest prospective VHL disease-specific therapeutic trial performed to date, and the data that show pazopanib resulted in significant and sustained disease control for the majority of patients enrolled on the study. (Abstract 4516)

Advertisement

Advertisement



Advertisement